What did @torifromtheblock actually say?
The transcript here is extremely thin. The only words captured are: "Is that what's happening? 100%. And what gave you the confidence? Delusion?" That's not much to work with factually, but the caption fills in the real story. Tori is describing fatigue as an "unbearable" Wegovy side effect, reporting almost no weight loss, and asking whether she might be one of the rare non-responders to semaglutide.
These are legitimate concerns shared by a large slice of the GLP-1 user community. The frustration is real, and the questions are medically relevant. The caption also tags insulin resistance, which is a clinically interesting detail that deserves attention.
Does the science back this up?
Yes, partially. Fatigue is a documented side effect of semaglutide, and slow early weight loss is also a real phenomenon, not a sign the drug has failed. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed average weight loss of around 14.9% of body weight over 68 weeks, but that average conceals significant individual variation.
A meaningful minority of patients lose far less. Analyses from real-world data, including Wharton et al. (2022, Obesity), show that roughly 10-15% of patients on GLP-1 receptor agonists are considered "low responders," meaning they lose less than 5% of body weight. Fatigue in early titration is often tied to the caloric restriction the drug enforces plus GI disruption, not a direct pharmacological toxicity. It typically improves as the body adapts.
What did they get wrong (or right)?
Tori gets credit for not catastrophizing. She is asking questions rather than declaring the drug dangerous, which is more than can be said for a lot of GLP-1 content online. The insulin resistance hashtag is also worth noting. Insulin resistance genuinely can blunt initial weight loss on semaglutide, and some research, including Bergman et al. (2023, Diabetes, Obesity and Metabolism), suggests metabolic phenotype affects GLP-1 response.
What she gets wrong, implicitly, is framing herself as potentially "the ONE person this doesn't work for." That framing understates how common slow early response actually is. Non-response at a few weeks is not non-response at 12 or 20 weeks. Dose titration exists for a reason. Early fatigue plus slow loss during the low-dose phase does not predict long-term outcome.
What should you actually know?
A few things matter here. First, Wegovy is titrated slowly over 16-20 weeks before reaching the 2.4 mg maintenance dose. Most of the meaningful weight loss in clinical trials happened at or after the full maintenance dose. Judging the drug's effectiveness during titration is like judging a race at the first 100 meters.
Second, fatigue is one of the most commonly underreported side effects in GLP-1 clinical trials. A 2023 systematic review (Shi et al., Frontiers in Endocrinology) found fatigue prevalence of 11-18% across GLP-1 receptor agonist studies, often peaking during dose escalation. It is not imaginary and it is not rare.
Third, if insulin resistance is in the picture, as Tori's hashtag suggests, that is a conversation to have with a prescriber. Some patients benefit from adjunct approaches. FormBlends does not recommend specific combinations, but the clinical picture should be reviewed by whoever is managing the prescription.
Bottom line
Tori's experience is frustrating but not unusual, and it does not mean she is a non-responder. The science says give it more time at full dose before drawing conclusions. The fatigue is real and documented. The slow early loss is common. Neither is a verdict on whether Wegovy will work for her.